Stocktoria
Acrivon Therapeutics, Inc. ACRV
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2022-11-15
Chart by TradingView
2/9
Piotroski F — financial health
0.9
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$84.1M | -$89.2M | -$67.1M | -$32.7M | -$16.2M |
| Net income | -$77.9M | -$80.6M | -$60.4M | -$31.2M | -$16.2M |
| Operating cash flow | -$63.7M | -$65.7M | -$42.6M | -$30.1M | -$14.0M |
| Free cash flow | -$65.3M | -$68.4M | -$43.9M | -$32.3M | -$14.2M |
| Total assets | $129.7M | $196.6M | $138.3M | $181.2M | $106.6M |
| Total liabilities | $17.2M | $19.8M | $17.1M | $10.8M | $7.9M |
| Shareholders' equity | $112.5M | $176.8M | $121.2M | $170.5M | -$23.8M |
| Ratios | |||||
| Return on assets | -60.1% | -41.0% | -43.7% | -17.2% | -15.2% |
| Return on equity | -69.2% | -45.6% | -49.8% | -18.3% | 68.2% |
| Current ratio | 7.69 | 10.55 | 9.75 | 20.27 | 34.46 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 758,440 | $1.1M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.9 (distress)
- Working capital / assets 0.808
- Retained earnings / assets -2.119
- EBIT / assets -0.648
- Equity / liabilities 6.541
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001781174 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.